Earnings call Transcript as on dated 15th May, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sanjivani Paranteral reported Q4 FY'26 standalone revenue of INR 105.1 million with EBITDA margin of 14.7%, while consolidated revenue was INR 132.1 million with EBITDA margin of 15.74%. The company attributed Q4 revenue decline to geopolitical disruptions between US and Iran that disrupted shipping routes and export logistics in March 2026, impacting their key Middle East markets. The new Pune IV infusion facility (started commercial production in December 2025) contributed INR 2.7 crore in Q4 versus INR 1.2 crore in Q3. Management guided for FY'27 revenue of INR 80-85 crore from base business and INR 60-65 crore from Pune IV plant, with EBITDA margins of 15.5-16.5% for base business and 17-18% for the Pune facility. The nutraceutical venture in Prague (45% owned) had revenue of EUR 500,000-600,000 in its first year but profits will be remitted only in FY'27.
The earnings call reveals near-term headwinds from geopolitical disruptions affecting exports, offset by positive management commentary on new business ramp-up and margin guidance. Investors should monitor the Pune facility's commercialization trajectory and whether the company can achieve its FY'27 targets amid ongoing geopolitical uncertainty.